

---

# JPMORGAN FUNDS - THEMATIC – GENETIC THERAPIES

---

Effective date 12 May 2021

Update to re-classify the Sub-Fund from “ESG Integrated” to “Thematic”, which is a sustainable Sub-Fund category.

The theme of Genetic Therapies is a sustainable theme and consistent with the UN Sustainable Development Goal of “Good Health and Wellbeing”. In this regard, the Sub-Fund can be reclassified as “Thematic” without any changes to the portfolio or how the Sub-Fund is managed.

This change will also not affect the risk profile of the Sub-Fund.

In addition, the “ESG Integration and Sustainable Investing Approaches” section of the prospectus will be updated to clarify that the thematic focus will be on a UN Sustainable Development Goal or other ESG theme.

If you have any questions about this change or any other aspect of JPMorgan Funds, please contact the Registered Office or your usual local representative.

---

Representative in Switzerland: JPMorgan Asset Management (Switzerland) LLC, Dreikönigstrasse 37, 8002 Zurich. Paying Agent in Switzerland: J.P. Morgan (Suisse) SA, 8 Rue de la Confédération, 1204 Geneva. The prospectus, the key investor information documents, the articles of incorporation and the annual and semi-annual financial report may be obtained free of charge from the representative.

LV-JPM53175 | CH/EN | 04/21